Opinion/decision on a Paediatric investigation plan (PIP): Exagamglogene autotemcel, decision type: , therapeutic area: , PIP number: P/0046/2023

Opinion/decision on a Paediatric investigation plan (PIP): Exagamglogene autotemcel, decision type: , therapeutic area: , PIP number: P/0046/2023

Human medicines European public assessment report (EPAR): Silodosin Recordati, silodosin, Prostatic Hyperplasia, Date of authorisation: 07/01/2019, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Silodosin Recordati, silodosin, Prostatic Hyperplasia, Date of authorisation: 07/01/2019, Revision: 2, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): diclofenac,orphenadrine (citrate), decision type: , therapeutic area: , PIP number: P/0036/2023

Opinion/decision on a Paediatric investigation plan (PIP): diclofenac,orphenadrine (citrate), decision type: , therapeutic area: , PIP number: P/0036/2023

Opinion/decision on a Paediatric investigation plan (PIP): rivaroxaban,Acetylsalicylic acid, decision type: , therapeutic area: , PIP number: P/0042/2023

Opinion/decision on a Paediatric investigation plan (PIP): rivaroxaban,Acetylsalicylic acid, decision type: , therapeutic area: , PIP number: P/0042/2023

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Lymphoma, Follicular, Date of authorisation: 03/06/2022, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Lunsumio, mosunetuzumab, Lymphoma, Follicular, Date of authorisation: 03/06/2022, Revision: 2, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Rosuvastatin (calcium),fenofibrate, decision type: , therapeutic area: , PIP number: P/0001/2023

Opinion/decision on a Paediatric investigation plan (PIP): Rosuvastatin (calcium),fenofibrate, decision type: , therapeutic area: , PIP number: P/0001/2023

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 18, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness